Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions


Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Using of CD10 in accordance with clinical and histological features of thyroid lesions could be used as both diagnostic and prognostic tool, which consequently influence the management and their prognosis for survival of patients with thyroid neoplasms especially papillary thyroid carcinoma (PTC). The aim of this study was to determine its expression in PTC and different benign thyroid lesions.
Materials and Methods: In this descriptive-analytic, cross-sectional study, paraffin-embedded tissues of patients with definitive pathologic diagnosis of different benign thyroid lesions and PTC were retrieved. Immunostained sections of each slides was performed using immunohistochemistry methods and expression of CD10 was compared in two groups of benign thyroid lesions and PTC.
Results: From selected cases 134 sections studied in two groups of PTC (n = 67) and benign thyroid lesions (n = 67). CD10 were immunohistochemically positive in 29.9% of PTC cases, but in none of the thyroid benign lesions (0%) (P < 0.001). There was not significant relationship between expression of CD10 with age and sex of the studied population (P > 0.05).
Conclusion: The results of the current study indicate that due to the higher expression of CD10 in PTC than benign thyroid lesions it might be used for differentiating mentioned lesions. But for using it as a diagnostic tool further studies with larger sample size and determination of its sensitivity, specificity and cut-off point is necessary.


Nikiforov YE. Thyroid tumors: Classification and general considerations. In: Nikiforov YE, Biddinger PW, Thompson LD, editors. Diagnostic Pathology and Molecular Genetics of the Thyroid. Philadelphia, PA; Lippincott Williams; 2009. p. 94-102.  Back to cited text no. 1
Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000;89:202-17.  Back to cited text no. 2
Baloch ZW, LiVolsi VA. Pathology of thyroid gland. In: Livolsi VA, Asa SL, editors. Endocrine Pathology. New York: Churchill Livingstone; 2002. p. 61-88.  Back to cited text no. 3
Khan A, Nose V. Pathology of thyroid gland. In: Lloyd RV, editor. Endocrine Pathology: Differential Diagnosis and Molecular Advances. 2 nd ed. New York: Springer: 2010. p. 181-236.  Back to cited text no. 4
DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Classification of Tumours. In: Kleihues P, Sobrin LH, series editors. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: World Health Organization, IARC Press; 2004.  Back to cited text no. 5
Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol 2011;5:51-6.  Back to cited text no. 6
DeVita VT, Hellman JS, Rosenberg SA. Cancer: Principles and Practice of Oncology. Philadelphia, Pa: Lippincott Williams and Wilkins; 2008. p. 1674-99.  Back to cited text no. 7
Franc B, de la Salmonière P, Lange F, Hoang C, Louvel A, de Roquancourt A, et al. Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 2003;34:1092-100.  Back to cited text no. 8
Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336-40.  Back to cited text no. 9
Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: The bane of the pathologist. Am J Clin Pathol 2002;117:143-50.  Back to cited text no. 10
Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S. Diagnostic applicability of dipeptidyl aminopeptidase IV activity in cytological samples for differentiating follicular thyroid carcinoma from follicular adenoma. Arch Surg 2004;139:83-8.  Back to cited text no. 11
El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008;3:5.  Back to cited text no. 12
Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA, et al. Classification of follicular thyroid tumors by molecular signature: Results of gene profiling. Clin Cancer Res 2003;9:1792-800.  Back to cited text no. 13
Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: Galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 2010;21:80-9.  Back to cited text no. 14
Magro G, Cataldo I, Amico P, Torrisi A, Vecchio GM, Parenti R, et al. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid 2011;21:267-77.  Back to cited text no. 15
Sethi K, Sarkar S, Das S, Mohanty B, Mandal M. Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol 2010;8:341-52.  Back to cited text no. 16
Fryknäs M, Wickenberg-Bolin U, Göransson H, Gustafsson MG, Foukakis T, Lee JJ, et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 2006;27:211-20.  Back to cited text no. 17
Mechtersheimer G, Möller P. Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors. Am J Pathol 1989;134:961-5.  Back to cited text no. 18
Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002;15:397-405.  Back to cited text no. 19
Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: A new predictor of clinical outcome. Virchows Arch 2002;440:589-93.  Back to cited text no. 20
Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002;33:1175-81.  Back to cited text no. 21
McCluggage WG, Oliva E, Herrington CS, McBride H, Young RH. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology 2003;43:144-50.  Back to cited text no. 22
Tomoda C, Kushima R, Takeuti E, Mukaisho K, Hattori T, Kitano H. CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma. Thyroid 2003;13:291-5.  Back to cited text no. 23
Yegen G, Demir MA, Ertan Y, Nalbant OA, Tunçyürek M. Can CD10 be used as a diagnostic marker in thyroid pathology? Virchows Arch 2009;454:101-5.  Back to cited text no. 24
Rezk S, Khan A. Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma. Appl Immunohistochem Mol Morphol 2005;13:256-64.  Back to cited text no. 25
Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 2000;113:374-82.  Back to cited text no. 26
Yasuda M, Itoh J, Satoh Y, Kumaki N, Tsukinoki K, Oqane N, et al. Availability of CD10 as a histopathological marker. Acta Histochem Cytochem 2005;38:17-24.  Back to cited text no. 27